Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Genetic Data Can Lead to Medical Discrimination: Opioid Use Disorder as a Cautionary Tale

Alexander S. Hatoum, Frank R. Wendt, Marco Galimberti, View ORCID ProfileRenato Polimanti, Benjamin Neale, Henry R. Kranzler, View ORCID ProfileJoel Gelernter, Howard J. Edenberg, Arpana Agrawal
doi: https://doi.org/10.1101/2020.09.12.20193342
Alexander S. Hatoum
1Washington University in St. Louis, School of Medicine, Department of Psychiatry, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ashatoum@wustl.edu
Frank R. Wendt
2Department of Psychiatry, Division of Human Genetics, Yale School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Galimberti
2Department of Psychiatry, Division of Human Genetics, Yale School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renato Polimanti
2Department of Psychiatry, Division of Human Genetics, Yale School of Medicine, New Haven, CT, USA
3Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Renato Polimanti
Benjamin Neale
4Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
5Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry R. Kranzler
6Center for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
7VISN 4 MIRECC, Crescenz VAMC, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Gelernter
2Department of Psychiatry, Division of Human Genetics, Yale School of Medicine, New Haven, CT, USA
3Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
8Department of Genetics, Yale School of Medicine, New Haven, CT, USA
9Department of Neuroscience, Yale School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joel Gelernter
Howard J. Edenberg
10Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
11Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arpana Agrawal
1Washington University in St. Louis, School of Medicine, Department of Psychiatry, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Using genetics to predict the likelihood of future psychiatric disorders, such as opioid use disorder (OUD), poses scientific and ethical challenges. Machine learning models are beginning to proliferate in psychiatry, however, most machine learning models in psychiatric genetics to date have not accounted for ancestry. Using an empirical example of a proposed genetic test for OUD and by generating a simulated random binary phenotype, we show that ML genetic prediction is completely confounded by ancestry, potentially discriminatory, and of no benefit for clinical practice. In an empirical example, we examine results from five ML algorithms trained with brain reward-derived “candidate” SNPs proposed for commercial use and demonstrate that the algorithms do not predict OUD better than chance when ancestry is balanced but are highly confounded with ancestry in an out-of-sample test set. We show how such a test could also predict subpopulations in admixed samples. Random sets of variants matched to the candidate SNPs by allele frequency produced similarly flawed predictions, further questioning the plausibility of selecting candidate variants. Finally, using random SNPs that predict a random simulated phenotype we show that the bias attributable to ancestral confounding would impact any such ML-based genetic prediction algorithm. Given the small and distributed single-variant genetic effect sizes associated with most psychiatric disorders, researchers and clinicians are encouraged to be skeptical of claims of high prediction accuracy from the growing number of ML-derived genetic algorithms, particularly when models are naive to polygenicity and ancestral confounding.

Competing Interest Statement

HRK is an advisory board member for Dicerna and a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Dicerna, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. HRK and JG are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018.

Funding Statement

This research is supported by MH109532. ASH acknowledges support from DA007261; AA acknowledges support from K02DA032573. Yale-Penn (phs000425.v1.p1; phs000952.v1.p1) was supported by National Institutes of Health Grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, and R01 AA017535 and the Veterans Affairs Connecticut and Philadelphia Veterans Affairs Mental Illness Research, Educational, and Clinical Centers.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Yale and UPenn (site-specific) IRB

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This research is supported by MH109532. ASH acknowledges support from DA007261; AA acknowledges support from K02DA032573; FRW acknowledges support from F32 MH122058. Yale-Penn (phs000425.v1.p1; phs000952.v1.p1) was supported by National Institutes of Health Grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, and R01 AA017535 and the Veterans Affairs Connecticut and Philadelphia Veterans Affairs Mental Illness Research, Education and Clinical Centers.

  • Disclosures: HRK is an advisory board member for Dicerna and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Amygdala Neurosciences, Arbor, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, Otsuka, Arbor, and Amygdala Neurosciences. HRK and JG are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018.

  • The following version includes a simulated phenotype and random genotypes to show that the confounding is generalizable to instances outside OUD and the specific empirical test we used as an example of the confounding. We also expanded background on discussion, so as to discuss how this work fits into a larger field of thought.

Data Availability

Results from learning curves and ML scripts will be made available upon publication.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 16, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Genetic Data Can Lead to Medical Discrimination: Opioid Use Disorder as a Cautionary Tale
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Genetic Data Can Lead to Medical Discrimination: Opioid Use Disorder as a Cautionary Tale
Alexander S. Hatoum, Frank R. Wendt, Marco Galimberti, Renato Polimanti, Benjamin Neale, Henry R. Kranzler, Joel Gelernter, Howard J. Edenberg, Arpana Agrawal
medRxiv 2020.09.12.20193342; doi: https://doi.org/10.1101/2020.09.12.20193342
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Genetic Data Can Lead to Medical Discrimination: Opioid Use Disorder as a Cautionary Tale
Alexander S. Hatoum, Frank R. Wendt, Marco Galimberti, Renato Polimanti, Benjamin Neale, Henry R. Kranzler, Joel Gelernter, Howard J. Edenberg, Arpana Agrawal
medRxiv 2020.09.12.20193342; doi: https://doi.org/10.1101/2020.09.12.20193342

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Addiction Medicine
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (144)
  • Anesthesia (47)
  • Cardiovascular Medicine (419)
  • Dentistry and Oral Medicine (72)
  • Dermatology (49)
  • Emergency Medicine (147)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (174)
  • Epidemiology (4906)
  • Forensic Medicine (3)
  • Gastroenterology (185)
  • Genetic and Genomic Medicine (689)
  • Geriatric Medicine (72)
  • Health Economics (193)
  • Health Informatics (636)
  • Health Policy (322)
  • Health Systems and Quality Improvement (209)
  • Hematology (86)
  • HIV/AIDS (157)
  • Infectious Diseases (except HIV/AIDS) (5408)
  • Intensive Care and Critical Care Medicine (333)
  • Medical Education (96)
  • Medical Ethics (24)
  • Nephrology (77)
  • Neurology (692)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (128)
  • Occupational and Environmental Health (211)
  • Oncology (447)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (91)
  • Pain Medicine (37)
  • Palliative Medicine (18)
  • Pathology (131)
  • Pediatrics (201)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (88)
  • Psychiatry and Clinical Psychology (787)
  • Public and Global Health (1832)
  • Radiology and Imaging (328)
  • Rehabilitation Medicine and Physical Therapy (142)
  • Respiratory Medicine (257)
  • Rheumatology (87)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (63)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (38)